From the other side of the consultation, briefly.

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

josh_phd_bmore said:

6 month update on cardiovascular risk: down 53 lbs, off blood pressure meds, A1C normalized.

This answered a question I did not know how to ask. Printing the relevant bit and taking it with me.

Clinical perspective, offered as context rather than as advice.

Dizziness and cardiovascular risk: I was lightheaded for the first 2 weeks. Root cause was a combination of reduced caloric intake and mild dehydration.

Fix: minimum 80-100oz water daily, don't skip meals even if you're not hungry (eat small protein-rich snacks), and stand up slowly from sitting/lying positions. Also check your blood pressure — GLP-1-induced weight loss can make BP meds too strong, requiring dose reduction.

EndoResFellow said:

Dizziness and cardiovascular risk: I was lightheaded for the first 2 weeks.

Adding a me-too, because a thread of one person's experience is not much use. The detail I would add is minor and it is already implied above.

Moderator note: the sourcing question belongs in the vendor section and has been split out.